NCT06960083 Transcranial Magnetic Stimulation in Misophonia
| NCT ID | NCT06960083 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Condition | Misophonia |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-09-02 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2025-09-02 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of the project is to assess the efficacy of parietal transcranial magnetic stimulation in misophonia. N=60 participants will undergo two transcranial magnetic stimulation sessions: one inhibitory and another excitatory. During both sessions, the parietal region will be stimulated. Participants will perform computerized tasks immediately before and after the stimulation, while EEG, heart rate, and skin temperature will be recorded. These recordings will be used to assess if TMS can be used to improve tolerance to misophonia triggers.
Eligibility Criteria
Inclusion Criteria: * Hypersensitive to presence of a specific sound, which may be accompanied by irritation, anger/outbursts, or fear. * Must be between the ages of 18 - 55. * Must be fluent in English since the study's instructions, surveys, and tasks will be in English. Exclusion Criteria: * Epilepsy or previous episode of convulsion or seizure. * Previous episode of fainting spell or syncope. * Head trauma. * Hearing problems. * Cochlear implant. * Metal in the brain, skull, or anywhere else in the body (e.g., splinters, fragments, clips, etc.). * Implanted neurostimulator (e.g., DBS, epidural/subdural, VNS). * Presence of cardiac pacemaker or intracardiac lines. * Presence of medication infusion device. * Use of pro-convulsant or epileptogenic medications. * Pregnancy. The risks associated with TMS exposure during gestation have not been studied extensively. We wish to safeguard the health of potential participants and their children. * Lactation. The risks associated with TMS during lactation and its effects on infant development have not been studied. We wish to safeguard the health of potential participants and their children. * Presence of Mania, Psychosis, Antisocial Personality Disorder, Borderline Personality Disorder, and Suicidal Ideation.
Contact & Investigator
Daniela Schiller, PhD
PRINCIPAL INVESTIGATOR
Icahn School of Medicine at Mount Sinai
Frequently Asked Questions
Who can join the NCT06960083 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 55 Years, studying Misophonia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06960083 currently recruiting?
Yes, NCT06960083 is actively recruiting participants. Contact the research team at shama.patel@mssm.edu for enrollment information.
Where is the NCT06960083 trial being conducted?
This trial is being conducted at New York, United States.
Who is sponsoring the NCT06960083 clinical trial?
NCT06960083 is sponsored by Icahn School of Medicine at Mount Sinai. The principal investigator is Daniela Schiller, PhD at Icahn School of Medicine at Mount Sinai. The trial plans to enroll 60 participants.